Patent Assignment
Reel/Frame 019640/0640
Assignment of Assignor's Interest
Recorded: 2007-08-03
Received: 2007-08-03
Pages: 11
Assignor
GREENVILLE HOSPITAL SYSTEM
Executed: 2007-08-02
Assignee
GHC RESEARCH DEVELOPMENT CORPORATION
701 GROVE ROAD, GREENVILLE, SC, 29605, UNITED STATES
Covered Properties
(43)
Macrophage transfection method
Application:
60/924,868 →
Combination therapy of hybrid cells with BCG injection for treating Cancer Patients
Application:
11/802,566 →
Combination therapy of hybrid cells with BCG injection for treating cancer patients
Application:
60/924,611 →
Macrophage transfection method
Application:
60/907,977 →
Polypeptides comprising Fas activation and NKG2D-ligand domains
Application:
60/907,586 →
Hybrid cells
Application:
11/702,661 →
Polypeptides comprising Fas activation and NKG2D-ligand domains
Application:
60/861,242 →
Use of anti-prolactin agents to treat proliferative conditions
Application:
11/498,962 →
Use of prolactin in the prophylactic treatment of cancer
Application:
60/763,892 →
Use of prolactin in the prophylactic treatment of cancer
Application:
60/728,297 →
Acetylated Therapeutic Procytotoxins
Application:
11/131,443 →
Therapeutic Pore-Forming Peptides
Application:
11/123,182 →
Front Face of a Vehicle Wheel
Application:
29/225,987 →
Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
Application:
11/073,927 →
Hybrid cells
Application:
11/017,733 →
Synthetic transcription regulators
Application:
60/636,612 →
Vegf Receptor Antagonists
Application:
10/985,013 →
Unitary Absorbent Multilayered Core
Application:
10/495,441 →
Anti-tumor vasculature effects of human serum albumin derivatives
Application:
10/813,432 →
Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
Application:
60/550,326 →
Antitumor agents comprising a targeting portion and an immune response triggering portion
Application:
10/792,390 →
VEGF receptor antagonists
Application:
60/518,295 →
AAV ITR-mediated modulation
Application:
10/669,641 →
Human Prolactin Antagonist-Angiogensis Inhibitor Fusion Proteins
Application:
10/449,609 →
Multimeric Ligands with Enhanced Stability
Application:
10/419,976 →
Metastasis modulating activity of highly sulfated oligosaccharides
Application:
10/409,607 →
Anti-tumor vasculature effects of human serum albumin derivatives
Application:
60/458,395 →
Antitumor agents comprising a targeting portion and an immune response triggering portion
Application:
60/451,253 →
AAV ITR-mediated modulation
Application:
60/413,450 →
Stable Episomal Vectors
Application:
10/231,467 →
GPI-anchored cytokines
Application:
10/228,262 →
Use of Anti-Prolactin Agents to Treat Proliferative Conditions
Application:
10/140,293 →
Multimeric ligands with enhanced stability
Application:
60/374,137 →
Metastasis modulating activity of highly sulfated oligosaccharides
Application:
60/370,730 →
Monocyte-Specific Particulate Delivery Vehicle
Application:
10/112,036 →
Stable episomal vectors
Application:
60/315,698 →
Lytic Peptide Prodrugs
Application:
09/938,623 →
GPI-anchored cytokines
Application:
60/314,653 →
Therapeutic Pore-Forming Peptides
Application:
09/851,422 →
Monocyte-specific particulate delivery vehicle
Application:
60/279,769 →
Bi-Functional Cancer Treatment Agents
Application:
09/815,306 →
Multiwavelength Laser for Illumination of Photo-Dynamic Therapy Drugs
Application:
09/795,650 →
Hybrid Cells
Application:
09/756,293 →